Terapia fotodinámica en pacientes con acné inflamatorio facial leve a moderadamente severo: estudio abierto en 30 pacientes chilenos / Photodynamic therapy in patients with inflammatory mild to moderate-severe acne

Introducción: La terapia fotodinámica es un procedimiento útil en el manejo del acné inflamatorio. Diversos esquemas terapéuticos se han usado. Objetivo: Demostrar eficacia y tolerancia de una sesión de TFD-MAL en el manejo del acné inflamatorio. Métodos: Una sesión de TFD-MAL y luz roja por cuatro minutos e incubación de tres horas fue realizada en 30 pacientes portadores de acné inflamatorio, leve, o moderadamente severo. Resultados: Resolución clínica de las lesiones o las seis semanas fue considerada buena (mejoría > 50%) en un 70% según evaluación médica y en un 66,6% según evaluación por el paciente. Se consignaron efectos adversos de eritema, descamación y rezumación leves dentro de las primeras 48 horas de la terapia en una gran proporción de pacientes. No se presentaron efectos adversos residuales o la semana 6. La encuesta de satisfacción relacionada a tolerancia y rapidez de acción demostró aceptación de la terapia en un 56% de los casos. Conclusión: La TFD-MAL con una sesión, incubación de tres horas y cuatro minutos de iluminación con luz roja constituye una buena alternativa terapéutica para el manejo del acné inflamatorio recalcitrante o en pacientes con contraindicaciones a terapias habituales.

Introduction: Photodynamic therapy is useful in the treatment of inflammatory acne. Several modalities have been used. Objective: To prove efficacy and tolerance of one session of PDT-MAL in the management of inflammatory acne. Methods: One session of PDT-MAL, for 4 minutes of red light, with an incubation period of 3 hours was performed in 30 patients with inflammatory mild to moderate-severe acne. Results: Clinical resolution at 6 weeks was considered good (resolution > 50%) in 70% of the patients under dermatologist evaluation and in 66.6% under patient evaluation. Adverse effects such as erythema, desquamation, oozoning were light and present in the first 48 hrs in o great proportion of cases. No adverse effects were seen at week 6. Satisfaction interview related to tolerance and speed of action showed good therapy acceptance in 56% of the patients. Conclusion: One session of PD T-MAL after 3 hours of incubation period and 4 minutes of red light is o good therapeutic option for the management of resistant inflammatory acne or to be used in patients with contraindication of common therapies for acne.

Terapia fotodinámica con metil aminolevulinato y ácido 5-aminolevulínico en acné inflamatorio leve y moderado: experiencia clínica / Photodynamic therapy with 5-aminolevulinic acid and methyl aminolevulinate for mild to moderate inflammatory acne: clinical experience

Introducción: La terapia fotodinámica (TFD) con ácido 5-aminolevulínico (ALA) y metil aminolevulinato (MAL) ha mostrado utilidad en el manejo del acné inflamatorio. Métodos: Dos grupos de cuatro pacientes cada uno, portadores de acné inflamatorio leve o moderado. Se realizaron dos sesiones de TFD separadas por dos semanas: un grupo fue tratado con MAL y luz roja y el otro, con ALA y luz azul. Se midió la severidad del acné con escala de 6 puntos y se consideró éxito clínico los grados 0 y 1. Resultados: En ambos grupos se observó éxito clínico a las 12 semanas post tratamiento, quedando con pigmentación residual, escasos comedones y menos de 10 pápulas. Se observaron efectos adversos tolerables, siendo los más importantes el eritema y la descamación. Conclusión: La TFD con ALA y MAL es una buena alternativa terapéutica para aquellos pacientes con acné inflamatorio leve y moderado que no responden o tienen contraindicación a los tratamientos convencionales.

Introduction: Photodynamic therapy with methyl aminolevulinate (MAL) and 5-aminolevulinic acid (ALA) has shown to be useful in the management of inflammatory acne. Methods: Two groups of 4 patients each with mild to moderate inflammatory acne. Two PDT sessions were performed within a 2 week interval; one group was treated with MAL and red light, and the other with ALA and blue light. Acne severity was measured with a 6-point scale and clinical success was considered between grades 0 and 1. Results: In both groups, clinical success was observed at 12 weeks post treatment, leaving residual pigmentation, scarce comedones and less than 10 papules. Tolerable side effects were observed, being the most important erythema and desquamation. Conclusion: PDT with ALA and MAL is a good therapeutic option for patients with mild to moderate inflammatory acne who do not respond or have contraindications to conventional treatments.

1,550-nm Non-ablative Fractional Erbium-Glass Laser in the Treatment of Facial Inflammatory Acne: A Preliminary Study / 대한피부과학회지

BACKGROUND: Topical and systemic drugs have been successfully used in the treatment of acne. However, many people are concerned about the side effects of these medicines, especially the childbearing women. Recent reports demonstrated that sequential treatment with laser- and light-based devices lead to a clinical improvement in acne. Recently, we witnessed experienced a case of improvement of inflammatory acne lesions during the treatment of acne scars using a 1,550-nm non-ablative fractional erbium-glass laser. OBJECTIVE: This study was designed to investigate the efficacy and safety of 1,550-nm non-ablative fractional erbium-glass laser in the treatment of facial inflammatory acne vulgaris. METHODS: 11 patients with facial inflammatory acne vulgaris were recruited. These patients received three treatment sessions at a 3-week interval. Inflammatory lesions were counted before and after treatment. The sebum production was quantified using the Sebumeter(R). We graded the patients' self-assessment and the investigator's global assessment using a five-point scale used by the dermatologist. We also investigated the histological changes after the treatment sessions, and the adverse effects during the study. RESULTS: Treatment with 1,550-nm non-ablative fractional erbium-glass laser was well tolerated, resulting in the reduction of inflammatory lesions by 61% (p<0.05). However, the reduction in sebum production from the baseline was not statistically significant. Histopathologic examination of the inflammatory lesions showed a marked decrease in the dermal inflammatory cell infiltration around the perivascular and periappendageal area and the sebaceous glands became smaller after laser treatments. Side-effects were minimal, and were resolved within a few days. CONCLUSION: 1,550-nm non-ablative fractional erbium-glass laser was safe and effective for the treatment of facial inflammatory acne lesions.